FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1891-1900 October 28, 2004 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The past two years have witnessed extraordinary regulatory ferment in the area of conflicts of interest involving physicians, especially conflicts arising in relationships with the pharmaceutical industry. Professional regulatory bodies, the pharmaceutical industry, and the government have all decided that physicians and drug manufacturers need stronger advice about appropriate relationships. In 2002, three leading professional organizations — the American Medical Association,¹ the American College of Physicians,² and the Accreditation Council for Continuing Medical Education³ — issued or revamped guidelines regarding physicians' interactions with drug companies. In July 2002, acting through its trade association, the Pharmaceutical Research and Manufacturers of America, . . . [Full Text of this Article]

Emergence of Conflicts of Interest Involving Pharmaceutical Companies

"Anti-Kickback" Law

Conflicts of Interest and the Lupron Case

Responses of the Industry and the Medical Profession

Guidance of the Office of the Inspector General

Conclusions

Source Information

From the Harvard School of Public Health (D.M.S., M.M.M., T.A.B.) and Harvard Medical School (T.A.B.) — both in Boston.

Address reprint requests to Dr. Brennan at Brigham and Women's Hospital, 75 Francis St., PBB4, Boston, MA 02115, or at tabrennan@partners.org.

This article has been cited by other articles:

• Arbuckle, M. R., Gameroff, M. J., Marcus, S. C., West, J. C., Wilk, J., Olfson, M. (2008). Brief Reports: Psychiatric Opinion and Antipsychotic Selection in the Management of Schizophrenia. Psychiatr. Serv. 59: 561-565 [Abstract] [Full Text]  
• Steinbrook, R. (2008). Financial Support of Continuing Medical Education. JAMA 299: 1060-1062 [Full Text]  
• Epstein, R. A (2007). Influence of pharmaceutical funding on the conclusions of meta-analyses. BMJ 335: 1167-1167 [Full Text]  
• Carroll, A. E., Vreeman, R. C., Buddenbaum, J., Inui, T. S. (2007). To What Extent Do Educational Interventions Impact Medical Trainees' Attitudes and Behaviors Regarding Industry-Trainee and Industry-Physician Relationships?. Pediatrics 120: e1528-e1535 [Abstract] [Full Text]  
• Campbell, E. G., Weissman, J. S., Ehringhaus, S., Rao, S. R., Moy, B., Feibelmann, S., Goold, S. D. (2007). Institutional Academic Industry Relationships. JAMA 298: 1779-1786 [Abstract] [Full Text]  
• Tonelli, M. R. (2007). Conflict of Interest in Clinical Practice. Chest 132: 664-670 [Abstract] [Full Text]  
• Pinto, S. L, Lipowski, E., Segal, R., Kimberlin, C., Algina, J. (2007). Physicians' intent to comply with the American Medical Association's guidelines on gifts from the pharmaceutical industry. J. Med. Ethics 33: 313-319 [Abstract] [Full Text]  
• Campbell, E. G., Gruen, R. L., Mountford, J., Miller, L. G., Cleary, P. D., Blumenthal, D. (2007). A National Survey of Physician-Industry Relationships. NEJM 356: 1742-1750 [Abstract] [Full Text]  
• Steinman, M. A., Chren, M.-M., Landefeld, C. S., Bero, L. A. (2007). The Promotion of Gabapentin. ANN INTERN MED 146: 313-314 [Full Text]  
• (2007). Bibliography for Ethics, Professionalism, and End of Life Care. Focus 5: 417-419 [Full Text]  
• Morgan, M A, Dana, J, Loewenstein, G, Zinberg, S, Schulkin, J (2006). Interactions of doctors with the pharmaceutical industry.. J. Med. Ethics 32: 559-563 [Abstract] [Full Text]  
• Steinman, M. A., Bero, L. A., Chren, M.-M., Landefeld, C. S. (2006). Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents. ANN INTERN MED 145: 284-293 [Abstract] [Full Text]  
• Olcott, C. IV (2006). The Pacific Coast Surgical Association in the New Millennium. Arch Surg 141: 729-733 [Full Text]  
• Brennan, T. A., Rothman, D. J., Blank, L., Blumenthal, D., Chimonas, S. C., Cohen, J. J., Goldman, J., Kassirer, J. P., Kimball, H., Naughton, J., Smelser, N. (2006). Health Industry Practices That Create Conflicts of Interest: A Policy Proposal for Academic Medical Centers. JAMA 295: 429-433 [Abstract] [Full Text]  
• Ducharme, J. (2005). Clinical Guidelines and Policies: Can they Improve Emergency Department Pain Management?. J Law Med Ethics 33: 783-790  
• McKoy, J. M., Lyons, E. A., Obadina, E., Carson, K., Pickard, A. S., Schellhammer, P., McLeod, D., Boyd, C. E., McWilliams, N., Sartor, O., Schumock, G. T., McCaffery, K., Bennett, C. L. (2005). Caveat Medicus: Consequences of Federal Investigations of Marketing Activities of Pharmaceutical Suppliers of Prostate Cancer Drugs. JCO 23: 8894-8905 [Abstract] [Full Text]  
• Sierles, F. S., Brodkey, A. C., Cleary, L. M., McCurdy, F. A., Mintz, M., Frank, J., Lynn, D. J., Chao, J., Morgenstern, B. Z., Shore, W., Woodard, J. L. (2005). Medical Students' Exposure to and Attitudes About Drug Company Interactions: A National Survey. JAMA 294: 1034-1042 [Abstract] [Full Text]  
• Norris, J. W. (2005). Antiplatelet Agents in Secondary Prevention of Stroke: A Perspective. Stroke 36: 2034-2036 [Abstract] [Full Text]  
• Chimonas, S., Rothman, D. J. (2005). New Federal Guidelines For Physician-Pharmaceutical Industry Relations: The Politics Of Policy Formation. Health Aff (Millwood) 24: 949-960 [Abstract] [Full Text]  
• Spurgeon, D. (2004). Companies may face tighter regulation over promoting drugs. BMJ 329: 998-998 [Full Text]